Product Name:
Fyn-pY213+pY214
Product Number:
ab-pk644
Target Full Name: Fyn proto-oncogene-encoded protein-tyrosine kinase
Target Alias: Fyn; Fyn oncogene related to SRC, FGR, YES; Kinase Fyn; MGC45350; P59-Fyn; P59-Fyn; SLK; SYN; hCG_34806; RP1-66H14.1-003; CCDS5094.1; ENSG00000010810
Product Type Specific: Fyn protein kinase phosphosite-specific antibody
Antibody Code: PK644
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y213+Y214
Protein UniProt: P06241
Protein SigNET: Fyn
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Fyn sequence peptide Cat. No.: PE-04AMP99
Antibody Immunogen Sequence: NGG(pY)(pY)ITT(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues N210 to T217; in the SH2 domain. The effects of Y213 and Y214 phosphorylation are unclear. These are the major in vivo phosphorylation sites in Fyn (≥1819 and ≥677 reports, respectively, by mass spectrometry). Fyn is known to be phosphorylated in vitro at Y213 by Fyn, and at Y214 by Fyn.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Medium immunoreactivity of a target-sized protein by Western blotting in A431 cells. Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Dog | Rat | Mouse | Platypus | Chicken | Frog | Zebra fish.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 50-60 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: Medium to strong cross-reactive proteins of ~250, 180, 150, 80 and 45 kDa are detected in A431 cells.
Related Product 1: Fyn (210-217) pY213+pY214 antibody blocking peptide (Cat. No.: PE-04AMP99)
Related Product 2: FynSubtide kinase substrate peptide (Cat. No.: PE-01BHL95)
Related Product 3: Fyn expression antibody (Cat. No.: AB-NK065-2)
Related Product 4: Fyn Y531 phosphorylation antibody (Cat. No.: AB-PK645)
Related Product 5: Fyn Y420 phosphorylation antibody (Cat. No.: AB-PK881)
Related Product 6: Fyn T12 phosphorylation antibody (Cat. No.: AB-PK901)
Scientific Background: Fyn is a protein-tyrosine kinase of the TK group and Src family. It is a non-receptor kinase that mediates cell growth, survival, and adhesion. This kinase is highly expressed and widely distributed in most tested human tissues. Fyn is inhibited by phosphorylation at Y531. Fyn has been shown to phosphorylate Dab1, an intracellular adaptor protein that interacts with amyloid precursor protein (APP) and apoE receptor 2 (apoEr2). The interaction of Fyn and Dab1 regulates the phosphorylation, trafficking, and processing of APP and apoEr2. Fyn can interact with Fyn-binding protein and the p85 subunit of PI3K. It has been shown to be part of a protein complex involving DCC and FAK, which is downstream of Netrin-1, a pathway important in promoting both axonal outgrowth and axonal guidance in path finding. Fyn may be an oncoprotein (OP) based on its similarity to other Src family kinases that are known oncoproteins. Fyn expression has been shown to be significantly increased in Chronic Myelogenous Leukemia (CML). Knockdown of Fyn with shRNA slows leukemia cell growth, inhibits clonogenicity, and leads to increased sensitivity to imatinib. Fyn has also been linked with the development of lung squamous cell carcinomas (LSCC), melanomas (metastatic) and epilepsy. The active form of the protein kinase normally acts to promote tumour cell proliferation. Fyn has been linked with estrogen-receptor negative breast cancer, which is related to breast and colon cancer, and it may affect breast, lymph node, or lung tissues. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis. This description may include information annotated by UniProt and/or Google AI.